[go: up one dir, main page]

AR028026A1 - Metodo para el tratamiento de la enfermedad del ojo seco con agonistas del receptor nicotinico de acetilcolina - Google Patents

Metodo para el tratamiento de la enfermedad del ojo seco con agonistas del receptor nicotinico de acetilcolina

Info

Publication number
AR028026A1
AR028026A1 ARP010101875A ARP010101875A AR028026A1 AR 028026 A1 AR028026 A1 AR 028026A1 AR P010101875 A ARP010101875 A AR P010101875A AR P010101875 A ARP010101875 A AR P010101875A AR 028026 A1 AR028026 A1 AR 028026A1
Authority
AR
Argentina
Prior art keywords
acetilcoline
treatment
receptor agonists
dry eye
eye disease
Prior art date
Application number
ARP010101875A
Other languages
English (en)
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of AR028026A1 publication Critical patent/AR028026A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
ARP010101875A 2000-04-21 2001-04-23 Metodo para el tratamiento de la enfermedad del ojo seco con agonistas del receptor nicotinico de acetilcolina AR028026A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/557,059 US6277855B1 (en) 2000-04-21 2000-04-21 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
AR028026A1 true AR028026A1 (es) 2003-04-23

Family

ID=24223897

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101875A AR028026A1 (es) 2000-04-21 2001-04-23 Metodo para el tratamiento de la enfermedad del ojo seco con agonistas del receptor nicotinico de acetilcolina

Country Status (8)

Country Link
US (1) US6277855B1 (es)
EP (1) EP1214062B1 (es)
JP (1) JP2003531168A (es)
AR (1) AR028026A1 (es)
AT (1) ATE253912T1 (es)
AU (1) AU2001253765A1 (es)
DE (1) DE60101201D1 (es)
WO (1) WO2001080844A2 (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US6455554B1 (en) * 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
AU2001247474A1 (en) * 2000-03-16 2001-09-24 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US6596740B2 (en) * 2000-10-24 2003-07-22 Richard L. Jones Nicotine mucosal spray
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US6852741B2 (en) * 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7069084B2 (en) * 2002-06-14 2006-06-27 Seefit Incorporated Method and apparatus for preventing and treating eyelid problems
CA2494506C (en) * 2002-08-02 2009-02-10 Nutraceutical Development Corporation Development of muscle mass in a mammal
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
CN1700894A (zh) * 2002-10-18 2005-11-23 莫利化学医药公司 使用羊毛硫抗生素治疗干眼病的方法
PT1565055E (pt) * 2002-11-08 2013-09-16 Mclean Hospital Corp Compostos para o tratamento da dependência e da privação de tabaco
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
MXPA05006781A (es) * 2002-12-20 2005-09-30 Mclean Hospital Corp Compuestos para la normalizacion del ciclo de dormir / despertar.
KR20130121196A (ko) 2003-01-22 2013-11-05 센주 세이야꾸 가부시키가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환 치료약의 눈의 국소 조직으로의 이행 방법
US20050013806A1 (en) * 2003-04-04 2005-01-20 Chang Min S. Use of contact lens for corneal cell transplant
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
AU2003296968A1 (en) * 2003-12-12 2005-07-14 Richard W. Yee Method and apparatus for preventing and treating eyelid problems
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
EP1753445A4 (en) * 2004-05-06 2009-05-20 Molichem Medicines Inc TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS
WO2005113002A1 (ja) * 2004-05-21 2005-12-01 Senju Pharmaceutical Co., Ltd. ムスカリン受容体作動薬を含有する眼科用経皮吸収型製剤
JP4932480B2 (ja) * 2004-06-03 2012-05-16 千寿製薬株式会社 アミド化合物を含有する角膜知覚回復剤
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
US20090215714A1 (en) * 2004-06-10 2009-08-27 Perry Renshaw Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
WO2007013661A1 (ja) * 2005-07-26 2007-02-01 Senju Pharmaceutical Co., Ltd. 眼科用経皮吸収型製剤
FR2889847B1 (fr) 2005-08-18 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
EP1933852B1 (en) 2005-09-27 2018-12-19 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
EP1952150B1 (en) 2005-11-23 2016-12-14 Genentech, Inc. Methods and compositions related to b cell assays
US20070237797A1 (en) * 2006-03-28 2007-10-11 Gholam A. Peyman Neural Conduit Agent Dissemination
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
US20110217387A1 (en) * 2008-05-16 2011-09-08 Axis, Inc. Pharmaceutical composition for treatment of fibromyalgia
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
CN102216289A (zh) * 2008-10-14 2011-10-12 塞扣吉尼克斯公司 烟碱乙酰胆碱受体配体及其用途
JP2012517402A (ja) * 2009-02-11 2012-08-02 ヘグルンド、エー．エス． 禁煙を目的としたニコチンを頬側吸収するための組成物
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
ES2739490T3 (es) 2010-11-16 2020-01-31 Univ Leland Stanford Junior Sistemas para el tratamiento del ojo seco
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
CN103732611B (zh) * 2011-01-10 2016-06-01 伊沃恩有限公司 β-肾上腺素能反向激动剂用于戒烟的用途
ES2822301T3 (es) 2011-06-10 2021-04-30 Tissuetech Inc Métodos de procesamiento de tejidos de soporte fetal
WO2013032938A1 (en) 2011-08-26 2013-03-07 Tissuetech, Inc. Methods of sterilizing fetal support tissues
US9132193B2 (en) 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
RU2510701C1 (ru) * 2012-12-19 2014-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения блефароконъюнктивальной формы синдрома сухого глаза
WO2014138709A1 (en) * 2013-03-08 2014-09-12 Oculeve, Inc. Devices and methods for treating dry eye in animals
EP2967817B1 (en) 2013-03-12 2021-03-10 Oculeve, Inc. Implant delivery devices and systems
CN105307718B (zh) 2013-04-19 2018-05-11 奥库利维公司 鼻刺激装置和方法
US9770583B2 (en) 2014-02-25 2017-09-26 Oculeve, Inc. Polymer formulations for nasolacrimal stimulation
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
US9687652B2 (en) 2014-07-25 2017-06-27 Oculeve, Inc. Stimulation patterns for treating dry eye
CN107106542B (zh) 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
US10207108B2 (en) 2014-10-22 2019-02-19 Oculeve, Inc. Implantable nasal stimulator systems and methods
EP3209370A4 (en) 2014-10-22 2018-05-30 Oculeve, Inc. Contact lens for increasing tear production
EP3721938A1 (en) 2014-10-22 2020-10-14 Oculeve, Inc. Stimulation devices and methods for treating dry eye
EP3215224A4 (en) * 2014-11-05 2018-06-27 Tissuetech, Inc. Compositions and method for promoting nerve growth and regeneration
WO2016109639A2 (en) 2014-12-31 2016-07-07 Brown J David Glaucoma treatment devices and methods
US11224588B2 (en) * 2015-05-21 2022-01-18 Ophtalmis Monaco Combination of lipoic acid and taurine as osmoprotective agent
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
AU2016331925B2 (en) * 2015-09-30 2021-04-22 Microoptx Inc. Dry eye treatment devices and methods
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
NZ746468A (en) * 2016-04-07 2023-06-30 Oyster Point Pharma Inc Methods of treating ocular conditions
BR122023020807A2 (pt) 2016-04-12 2023-12-12 Arturo Solis Herrera Uso de agonistas do receptor de acetilcolina nicotínica no tratamento de uma condição de uma membrana mucosa nasal ou paranasal
AU2017260237A1 (en) 2016-05-02 2018-11-22 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
CA3045018A1 (en) 2016-12-02 2018-06-07 Oculeve, Inc. Apparatus and method for dry eye forecast and treatment recommendation
WO2020014217A1 (en) * 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
TW202317111A (zh) * 2021-07-07 2023-05-01 坎培拉大學 治療及抑制方法
DE102023208057A1 (de) 2023-08-23 2025-02-27 Ursapharm Arzneimittel Gmbh Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868154A (en) 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
KR100272614B1 (ko) 1992-08-31 2000-11-15 엠. 잭 오해니언 신경계의 퇴행성 질환의 치료에 유용한 아나바세인 유도체
US5817679A (en) 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
DE19626373A1 (de) * 1996-07-02 1998-01-08 Boehringer Ingelheim Kg Neuartige Verwendung von Wirkstoffen, welche die Funktion von nichtneuronalem Acetylcholin beeinflussen
US5830904A (en) 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds

Also Published As

Publication number Publication date
ATE253912T1 (de) 2003-11-15
WO2001080844A3 (en) 2002-03-28
EP1214062B1 (en) 2003-11-12
EP1214062A2 (en) 2002-06-19
JP2003531168A (ja) 2003-10-21
WO2001080844A2 (en) 2001-11-01
DE60101201D1 (de) 2003-12-18
US6277855B1 (en) 2001-08-21
AU2001253765A1 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
AR028026A1 (es) Metodo para el tratamiento de la enfermedad del ojo seco con agonistas del receptor nicotinico de acetilcolina
PT1189916E (pt) N-pirazole agonistas do receptor a2a
AR028579A1 (es) Metodo para el tratamiento de la sequedad vaginal, con agonistas del receptor de acetilcolina nicotinica
NO20030213D0 (no) Anvendelse av D2/D3 reseptor-agonister for behandling av fibromyalgi
DK1192169T3 (da) C-pyrazol A2A receptor-agonister
EE200200355A (et) EP4 retseptori selektiivsed agonistid osteoporoosi raviks
NO20014824L (no) Bicykliske heteroaromatiske forbindelser anvendelige som LH- agonister
EE200100075A (et) 2-asendatud 1-piperidüülbensimidasoolühendid kui ORL-1 retseptori agonistid
EP1608315A4 (en) TREATMENT OF IMMUNOLOGICAL DISORDERS USING INTERLEUKIN-21 / INTERLEUKIN-21 RECEPTOR
WO2005097140A3 (en) Selective antagonists of a2a adenosine receptors
DE60330392D1 (de) Cb 1 rezeptor inversagonisten
PT1292591E (pt) Derivados biciclicos substituidos para o tratamento de crescimento de celula anormal
SMP200600024B (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina
PT1049689E (pt) Compostos de 4-(2-ceto-1-benzimidazolinil)piperidina como agonistas do receptor orl1
NO20020574L (no) Substituerte 1,5-dihydropyrrol-2-on derivater som er virksomme som NMDA-reseptorantagonister for behandlingen avsmertetilstanden
PT1192170E (pt) Agonistas de receptor a2a de propargilfenileter
NO20015288D0 (no) Anvendelse av makrolide forbindelser for behandling av tört öye
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
PT1321135E (pt) Composicao para o tigimento de oxidacao das fibras ceratinicas
NO20043366L (no) Kortikotropinfrigjorende faktor-2 reseptoragonister
ES1051709Y (es) Fosa para la descomposicion de cadaveres animales.
DK1267606T3 (da) Malkeapparat med forbehandlingssystem
ES1049094Y (es) Dispositivo para la formacion de chaflanes en encofrados.
ES1042330Y (es) Colgador perfeccionado para prendas de vestir.
ES1054998Y (es) Cabestrillo para la sujecion de extremidades superiores.

Legal Events

Date Code Title Description
FB Suspension of granting procedure